Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY6 | O43306 | 1/20 | 0.57 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.57 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.57 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.57 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.57 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.57 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.57 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.57 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.57 |
| ▸ | PNMT | P11086 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21475687 | 1.00 | ADCY6 (0.57) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL25344633 | 0.98 | ADCY6 (0.55) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL232676 | 0.86 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL4575618 | 0.86 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL30578817 | 0.86 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL30578821 | 0.86 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL3503361 | 0.84 | ADCY6 (0.74) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Hydrochloric Acid SCHEMBL3322965 | 0.84 | ADCY6 (0.74) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL20909783 | 0.77 | PNMT (0.52) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL20909790 | 0.77 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ABCB1, CYP3A5, CYP3A7 | ADCY6 2291/4885ADCY3 2257/4885ADCY9 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.